Head-to-head · WeighScore
HealthRX vs NexLife
The verdict
HealthRX takes it — 77.5/100 to 61.9/100.
HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthRX’s current injection plans disclose the first charge and renewal separately. The lowest monthly equivalents require a prepaid year; a monthly subscription offers a smaller initial commitment.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | HealthRX | NexLife |
|---|---|---|
| WeighScore | 77.5/100 | 61.9/100 |
| Grade | C+ | C |
| Site position | #36 | #317 |
| Semaglutide | $149 first month, then $165/month; $1,163 per 12-month subscription | $165/mo (compounded) |
| Tirzepatide | $193 first month, then $214/month; $2,123 per 12-month subscription | $215/mo (compounded) |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Site position #36 · C+
Strengths
- Product pages publish due-today and next-charge tables
- Medication if approved, provider review and overnight shipping are included
- Longer plans offer a one-time purchase option without automatic renewal
Where it loses points
- Annual headline rates require payment for 12 months upfront
- Monthly subscription prices rise after the first payment
- Product navigation still shows older starting prices
- Injection supplies are not confirmed as standard inclusions
Site position #317 · C
FDAWarning letter issued to Nexlife Inc. dba Nexlife in June 2026. See the FDA warning-letter database.
Strengths
- LegitScript certified platform
- Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
- Both semaglutide and tirzepatide at competitive pricing
- Semaglutide from $145/mo on the 12-month plan ($165/mo month-to-month) - among the lowest in the dataset
Where it loses points
- State availability not publicly disclosed
- Compounded only — no brand-name options
- Also covers hormone optimization and longevity
- Lowest advertised rates ($145 sema / $186 tirz) require a 12-month plan commitment
- FDA issued Nexlife Inc. dba Nexlife a warning letter in June 2026; the letter is public in FDA's warning-letter database
Featured provider
HealthRX
HealthRX scores 77.5/100 (C+). HealthRX’s current injection plans disclose the first charge and renewal separately. The lowest monthly equivalents require a prepaid year; a monthly subscription offers a smaller initial commitment.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.